Enhanced Multi-Signal Fluorescent Probe for Early Tumor Diagnosis

An improved multi-signal fluorescent probe for early tumor diagnosis, featuring a modified structural formula with a hydrophilic linker, solvent-free microwave-assisted synthesis, and optional fluorescent quencher and biocompatible nanoparticle encapsulation.

The original multi-signal fluorescent probe, disclosed in Chinese Patent Application No. 202210441449.6, had limitations in terms of solubility, bioavailability, and reaction efficiency. The new inventive concept addresses these limitations by introducing a hydrophilic linker, microwave-assisted reaction, and optional fluorescent quencher and biocompatible nanoparticle encapsulation, resulting in an enhanced probe with improved performance and efficiency.

The enhanced multi-signal fluorescent probe features a modified structural formula incorporating a hydrophilic linker, which improves its solubility and bioavailability. The probe can be synthesized using a solvent-free microwave-assisted reaction, reducing reaction time and improving yield. Additionally, the reaction can be performed at a controlled temperature of 80-90°C to optimize reaction efficiency. The probe can further be modified by incorporating a fluorescent quencher to minimize background fluorescence and improve signal-to-noise ratio. Finally, the probe can be encapsulated in a biocompatible nanoparticle to enhance its stability and targeting efficiency.

The new inventive concept introduces a hydrophilic linker, microwave-assisted synthesis, and optional fluorescent quencher and biocompatible nanoparticle encapsulation, which are not present in the original patent. These features provide a significant improvement in the probe's performance and efficiency, making the new concept novel and non-obvious.

Alternative embodiments of the enhanced probe could include different types of hydrophilic linkers, varying microwave-assisted reaction conditions, and different fluorescent quenchers or biocompatible nanoparticles. These variations could be used to optimize the probe's performance for specific applications or target tissues.

The enhanced multi-signal fluorescent probe has significant commercial potential in the field of early tumor diagnosis, particularly in the development of point-of-care diagnostic devices and personalized medicine. The target market includes research institutions, hospitals, and biotechnology companies focused on cancer diagnosis and treatment.